Cencora, Inc. COR 72.58
Health Care · NYSE · Data as of 2026-08-05
Cencora, Inc. (COR) has delivered +9.4% annualized revenue growth, n/a earnings growth, and +4.3% dividend growth over 10 years of data. Ranked #206 of 1968 stocks overall and #22 of 260 in the Health Care sector by Steady Score.
About Cencora, Inc.
Company Overview
Cencora distributes pharmaceuticals and provides services across the medicine supply chain. It delivers brand-name, generic and specialty drugs to pharmacies, hospitals, clinics and other healthcare providers. The company also supports manufacturers with clinical-trial logistics, commercialization, patient access and animal-health distribution. Customers rely on its warehouses, ordering systems and controlled supply processes for timely access to regulated products.
Read more
Business Model & Revenue
Revenue is generated mainly by purchasing pharmaceuticals and reselling them at high volume and relatively narrow margins. Distribution agreements, generic sourcing, specialty services and manufacturer programs shape gross profit more than revenue alone. U.S. Healthcare Solutions is the largest segment; International Healthcare Solutions adds distribution and manufacturer services abroad. Prescription volumes, drug prices, customer mix and contract terms drive results.
Key Facts & Market Position
Cencora occupies an intermediary position between drug manufacturers and fragmented healthcare providers. Scale in secure logistics, purchasing and regulatory compliance is crucial because products may be high-value, temperature-sensitive or controlled. Large supplier and customer relationships create concentration, while specialty medicines and manufacturer services broaden the business beyond conventional wholesale distribution.